Madison-based ConjuGon has raised another $1.1 million from angel investors to fund research and development of its technology that can aid companies in developing new drugs to fight antibiotic-resistant bacteria, which annually are responsible for hundreds of thousands of deaths worldwide.
Office of Strategic Communication